In early clinical trials, patients suffering from advanced, treatment resistant cancers, showed a 90 percent halter in tumour growth or shrinkage.
This approach utilises the immune system’s natural rejection of foreign organ transplants to eliminate cancer cells, paving the way for a new direction in cancer therapy.